Skip to Content Facebook Feature Image

FF EAI Robotics Ecosystem Announces Strategic Partnership with California Science and Technology University and Boston International Business School to Advance Robotics Education, Talent Development, and Innovation

Business

FF EAI Robotics Ecosystem Announces Strategic Partnership with California Science and Technology University and Boston International Business School to Advance Robotics Education, Talent Development, and Innovation
Business

Business

FF EAI Robotics Ecosystem Announces Strategic Partnership with California Science and Technology University and Boston International Business School to Advance Robotics Education, Talent Development, and Innovation

2026-11-05 10:30 Last Updated At:11:06

LOS ANGELES, Nov. 5, 2026 /PRNewswire/ -- FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) ("FFR," "the Company"), a U.S.-based Embodied AI robotics company, today announced that it has entered into a comprehensive strategic partnership with California Science and Technology University (CSTU) and Boston International Business School (BIBS), strengthening and expanding an existing collaborative relationship across robotics education, research, talent cultivation, and innovation. The strategic partnership was formally announced during FFR's deal closing event held in New York on October 26, attended by FFR EAI Device Business Group President Chris Chen, where representatives from all three organizations participated in a signing ceremony marking the next phase of cooperation.

A video of the signing ceremony can be viewed here: https://youtu.be/bOevi0wsFLQ

The partnership encompasses several key initiatives, including strategic investment collaboration, joint development of robotics developer platform capabilities, operational support for CSTU's Boston campus, the planned establishment of the BIBS-FF-CSTU Joint Robotics Lab, and the development of new talent training programs designed to prepare students and developers for the rapidly growing embodied AI and robotics industries.

"This partnership reflects our commitment to building a comprehensive robotics ecosystem that connects technology innovation, education, research, and workforce development," said YT Jia, CEO of FF EAI Robotics Ecosystem Inc. "By bringing together industry and academic leaders, we aim to help cultivate the next generation of robotics and AI talent while accelerating innovation through collaborative research and developer engagement."

Under the MOU, FFR, CSTU, and BIBS will explore opportunities to jointly advance robotics education programs, support developer communities, and create pathways for students, researchers, and entrepreneurs to participate in the evolving embodied AI economy. The planned BIBS-FF-CSTU Joint Robotics Lab is expected to serve as a platform for interdisciplinary research, hands-on robotics development, and industry-academic collaboration.

"We are pleased to deepen our relationship with FFR and BIBS through this comprehensive strategic partnership," said Zhigang Qin, President of California Science and Technology University. "By combining academic resources, industry expertise, and innovation-driven programs, we believe this collaboration can provide meaningful opportunities for students and researchers while helping support the advancement of robotics technologies."

Professor Liya Rong, Dean of Boston International Business School, Co-Dean of the BIBS-FF-CSTU AI Robotics Institute, and Head of Operations for CSTU's Boston campus, said: "The convergence of artificial intelligence, robotics, and education is creating unprecedented opportunities for innovation. Through this partnership, we look forward to expanding collaborative research initiatives, strengthening academic-industry connections, and developing talent capable of contributing to the future of intelligent robotics systems."

The signing ceremony was witnessed by Professor Ugoji A. Eze, an international lawyer, AI and cybersecurity expert, and professor at the BIBS-FF AI-Robotics Institute. Professor Eze also participates in global policy discussions at the United Nations and has been an advocate for responsible innovation and international collaboration in emerging technologies.

The partnership is intended to further strengthen FFR's leadership position in robotics education by fostering collaboration across technology development, academic research, talent cultivation, and innovation ecosystems. Through these efforts, the parties aim to contribute to the advancement of embodied AI and robotics while preparing future generations of students and professionals for opportunities in the rapidly evolving sector.

ABOUT FF EAI ROBOTICS ECOSYSTEM INC.

FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is a U.S.-based Embodied AI robotics company focused on the research and development, manufacturing, commercialization and deployment of intelligent robotic technologies, products and industry solutions. FFR is building a "Four-Core Full-Stack" AI ecosystem covering the full lifecycle of robotics, consisting of EAI Brain & Developer Platform, EAI Devices, Industry Productivity Solutions, and EAI Data Factory. Guided by the technology and product philosophy of "One Brain, Multi-forms, Multi-capabilities," FFR aims to empower humanoid, biomimetic, and other robotic form factors through a unified EAI Brain, while continuously expanding their multi-task and multi-scenario capabilities. The ecosystem is designed to support the full robotics lifecycle, including R&D, deployment, data collection and training, operations, and commercial applications. FFR also operates RoboShare, a robot-sharing and services platform. To learn more, visit www.ff.com 

FORWARD LOOKING STATEMENTS

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Statements other than historical facts, including statements regarding the standalone full-year 2026 guidance for the acquired robotics business, expected sales and shipments, projected revenue and unit sales under the five-year business plan, expected gross margins, planned partnerships and access to government procurement opportunities, FFR's business strategy, commercialization plans, robotics operations, anticipated benefits of the acquisition, future growth opportunities and development and deployment of robotics technologies, are forward-looking statements. You can often identify forward-looking statements by words such as "may," "might," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "likely," or "continue," or the negative of these terms or other similar expressions; the absence of these words does not mean a statement is not forward-looking.

These statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the risk that the standalone guidance and longer-term projections are not achieved; FFR's ability to successfully integrate and operate the acquired business, commercialize its robotics technologies, achieve its business objectives, obtain additional financing, maintain compliance with Nasdaq listing requirements, compete effectively, manage its liquidity position and execute its strategic transition.

Additional risks and uncertainties are described in FFR's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and subsequent filings available at www.sec.gov.

Forward-looking statements speak only as of the date of this release. Forward-looking statements are based on management's current expectations and assumptions, are not guarantees of future performance and speak only as of the date of this release. Except as required by applicable law, FFR undertakes no obligation to update or revise any forward-looking statements.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

FF EAI Robotics Ecosystem Announces Strategic Partnership with California Science and Technology University and Boston International Business School to Advance Robotics Education, Talent Development, and Innovation

FF EAI Robotics Ecosystem Announces Strategic Partnership with California Science and Technology University and Boston International Business School to Advance Robotics Education, Talent Development, and Innovation

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system

SINGAPORE, Nov. 5, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.

The study marks an important and planned transition from studying genomics primarily in healthy volunteers to studying those with a broad range of medical conditions. By connecting genomic information with real-world health data, SG-INSIGHT aims to better understand disease and treatment responses, support the responsible introduction of genetic screening in Singapore's public healthcare system, and help healthcare become more tailored to individuals over time.

"Singapore is showing what the future of precision medicine can look like at national scale," said Jacob Thaysen, Chief Executive Officer of Illumina. "By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease, generate evidence that support more informed care decisions, and ultimately move healthcare toward earlier, more precise intervention. We are proud to bring Illumina's technology, expertise and longstanding presence in Singapore to help make that vision possible."

"Phase III builds on nearly a decade of precision medicine in Singapore," said Professor Patrick Tan, Executive Director of PRECISE. "By extending the programme to patients across the public healthcare system, SG-INSIGHT aims to deepen understanding of how genetic, lifestyle and environmental factors are associated with health and disease. Phase III reflects Singapore's ambition to build a trusted and sustainable precision health ecosystem grounded in the needs and diversity of its population."

Illumina will perform the sequencing in Singapore through its local genomics facility where scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing, and genomic data analysis. Co-located with Illumina's manufacturing and R&D operations, the facility will seek the necessary accreditation and comply with Singapore's Healthcare Services Act 2020 (HCSA), strengthening its commitment to quality, safety, regulatory compliance and biomedical innovation. 

Illumina's selection for the SG-INSIGHT Study was awarded through an international competitive tender. It builds on an existing multi-year engagement, through which Illumina supported the successful implementation and delivery of NPM Phase II, PRECISE-SG100K, covering more than 100,000 genomes from healthy volunteers.

"For nearly two decades, Singapore has been one of Illumina's most important centres for innovation, manufacturing and talent in Asia Pacific," said Nilesh Shah, Head of Region, Asia Pacific, Illumina. "Our long-standing relationship with PRECISE represents the next chapter in that commitment - combining Singapore's leadership in precision health with Illumina's local genomic capabilities and regional expertise. We remain committed to investing in the people, technology and partnerships that can help advance genomics responsibly in Singapore and across the region."

Illumina established its presence in Singapore in 2008. Today, Singapore serves as the company's Asia Pacific regional headquarters and one of its largest hubs outside the United States, with more than 1,700 employees across three locations. Illumina operations in Singapore encompass commercial operations, manufacturing, and R&D, supporting global research and innovation across sequencing platforms, software, and emerging technologies.

About PRECISE

Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore's multi-phase National Precision Medicine (NPM) programme. Established to drive a whole-of-Singapore effort, PRECISE works with research, clinical and industry partners to generate insights into Asian genomics and translate these into better health outcomes and economic opportunities.

PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore. NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734).

www.npm.sg

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Recommended Articles